Annual SG&A:
$0.00-$18.95M(-100.00%)Summary
- As of today, ELVN annual SG&A is $0.00, with the most recent change of -$18.95 million (-100.00%) on December 31, 2024.
- During the last 3 years, ELVN annual SG&A has fallen by -$4.29 million (-100.00%).
- ELVN annual SG&A is now -100.00% below its all-time high of $18.95 million, reached on December 31, 2023.
Performance
ELVN SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly SG&A:
$0.00-$7.09M(-100.00%)Summary
- As of today, ELVN quarterly SG&A is $0.00, with the most recent change of -$7.09 million (-100.00%) on September 30, 2025.
- Over the past year, ELVN quarterly SG&A has dropped by -$5.81 million (-100.00%).
- ELVN quarterly SG&A is now -100.00% below its all-time high of $7.09 million, reached on June 30, 2025.
Performance
ELVN Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM SG&A:
-$1.13B-$97.21M(-9.41%)Summary
- As of today, ELVN TTM SG&A is -$1.13 billion, with the most recent change of -$97.21 million (-9.41%) on September 30, 2025.
- Over the past year, ELVN TTM SG&A has dropped by -$1.15 billion (-5139.85%).
- ELVN TTM SG&A is now -1724.07% below its all-time high of -$61.97 million.
Performance
ELVN TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Selling, General & Administrative Expenses Formula
SG&A = Total Operating Expenses - Cost of Goods Sold - Research & Development
ELVN Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | -100.0% | -100.0% | -5139.9% |
| 3Y3 Years | -100.0% | -100.0% | -10000.0% |
| 5Y5 Years | -100.0% | -100.0% | -10000.0% |
ELVN Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | -100.0% | at low | -100.0% | at low | -129.3% | at low |
| 5Y | 5-Year | -100.0% | at low | -100.0% | at low | -259.0% | at low |
| All-Time | All-Time | -100.0% | at low | -100.0% | at low | -1724.1% | at low |
ELVN Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $0.00(-100.0%) | $20.06M(-22.5%) |
| Jun 2025 | - | $7.09M(+4.3%) | $25.87M(+5.4%) |
| Mar 2025 | - | $6.80M(+10.1%) | $24.56M(+3.3%) |
| Dec 2024 | $0.00(-100.0%) | $6.17M(+6.2%) | $23.78M(+6.0%) |
| Sep 2024 | - | $5.81M(+0.6%) | $22.43M(+5.5%) |
| Jun 2024 | - | $5.78M(-4.0%) | $21.26M(+4.0%) |
| Mar 2024 | - | $6.02M(+24.7%) | $20.43M(+7.8%) |
| Dec 2023 | $18.95M(+23.6%) | $4.82M(+3.9%) | $18.95M(+10.2%) |
| Sep 2023 | - | $4.64M(-6.2%) | $17.21M(+9.8%) |
| Jun 2023 | - | $4.95M(+9.1%) | $15.67M(+32.8%) |
| Mar 2023 | - | $4.54M(+47.5%) | $11.80M(+32.9%) |
| Dec 2022 | $15.33M | $3.08M(-0.9%) | $8.88M(-4.3%) |
| Sep 2022 | - | $3.10M(+187.8%) | $9.28M(-1.7%) |
| Jun 2022 | - | $1.08M(-33.4%) | $9.44M(-17.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $1.62M(-53.5%) | $11.45M(-11.9%) |
| Dec 2021 | $4.29M(-55.1%) | - | - |
| Dec 2021 | - | $3.48M(+6.6%) | $13.00M(+7.3%) |
| Sep 2021 | - | $3.26M(+5.4%) | $12.11M(+2.5%) |
| Jun 2021 | - | $3.10M(-2.2%) | $11.81M(+5.9%) |
| Mar 2021 | - | $3.17M(+22.2%) | $11.15M(+16.8%) |
| Dec 2020 | $9.54M(+86.9%) | $2.59M(-12.5%) | $9.54M(+37.3%) |
| Sep 2020 | - | $2.96M(+21.7%) | $6.95M(+21.3%) |
| Jun 2020 | - | $2.43M(+56.1%) | $5.73M(+73.7%) |
| Mar 2020 | - | $1.56M(-10.5%) | $3.30M(+89.5%) |
| Dec 2019 | $5.11M(+109.5%) | - | - |
| Sep 2019 | - | $1.74M | $1.74M |
| Dec 2018 | $2.44M(+147.0%) | - | - |
| Dec 2017 | $987.00K | - | - |
FAQ
- What is Enliven Therapeutics, Inc. annual SG&A?
- What is the all-time high annual SG&A for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. annual SG&A year-on-year change?
- What is Enliven Therapeutics, Inc. quarterly SG&A?
- What is the all-time high quarterly SG&A for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. quarterly SG&A year-on-year change?
- What is Enliven Therapeutics, Inc. TTM SG&A?
- What is the all-time high TTM SG&A for Enliven Therapeutics, Inc.?
- What is Enliven Therapeutics, Inc. TTM SG&A year-on-year change?
What is Enliven Therapeutics, Inc. annual SG&A?
The current annual SG&A of ELVN is $0.00
What is the all-time high annual SG&A for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high annual SG&A is $18.95M
What is Enliven Therapeutics, Inc. annual SG&A year-on-year change?
Over the past year, ELVN annual SG&A has changed by -$18.95M (-100.00%)
What is Enliven Therapeutics, Inc. quarterly SG&A?
The current quarterly SG&A of ELVN is $0.00
What is the all-time high quarterly SG&A for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high quarterly SG&A is $7.09M
What is Enliven Therapeutics, Inc. quarterly SG&A year-on-year change?
Over the past year, ELVN quarterly SG&A has changed by -$5.81M (-100.00%)
What is Enliven Therapeutics, Inc. TTM SG&A?
The current TTM SG&A of ELVN is -$1.13B
What is the all-time high TTM SG&A for Enliven Therapeutics, Inc.?
Enliven Therapeutics, Inc. all-time high TTM SG&A is -$61.97M
What is Enliven Therapeutics, Inc. TTM SG&A year-on-year change?
Over the past year, ELVN TTM SG&A has changed by -$1.15B (-5139.85%)